Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

被引：7

作者：

Shastri, Aditi ^{[1
,2
]}

Feldman, Eric J. ^{[1
,2
]}

Starodub, Alexander N. ^{[3
]}

Feldman, Tatyana ^{[4
]}

Rodriguez, Cristina P. ^{[5
]}

Epstein-Peterson, Zachary D. ^{[6
]}

Stevens, Don A. ^{[7
]}

Olszewski, Adam J. ^{[8
,9
]}

Huen, Auris O. ^{[10
]}

Porcu, Pierluigi ^{[11
]}

Reneau, John C. ^{[12
]}

Barta, Stefan K. ^{[13
]}

Marchi, Enrica ^{[14
]}

Mattour, Ahmad H. ^{[15
]}

Pinter-Brown, Lauren C. ^{[16
]}

Perea, Rachelle ^{[17
]}

Donohue, Sean ^{[17
]}

Dey, Joyoti ^{[17
]}

Agarwal, Sagar ^{[17
]}

Karnik, Rahul ^{[17
]}

Gollerkeri, Ashwin ^{[17
]}

Gollob, Jared ^{[17
]}

Smith, Stephen D. ^{[18
]}

机构：

[1] Montefiore Med Ctr, Dept Oncol, 111 E 210Th St, Bronx, NY 10467 USA

[2] Albert Einstein Coll Med, Bronx, NY 10467 USA

[3] Christ Hosp, Canc Ctr, Cincinnati, OH 45219 USA

[4] Hackensack Meridian Hlth, Lymphoma Div, John Theurer Canc Ctr, Hackensack, NJ USA

[5] Univ Washington, Div Med Oncol, Seattle, WA 98195 USA

[6] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, 1275 York Ave, New York, NY 10021 USA

[7] Norton Canc Inst, Louisville, KY USA

[8] Brown Univ, Providence, RI 02912 USA

[9] Lifespan Canc Inst, Providence, RI USA

[10] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[11] Thomas Jefferson Univ, Dept Med Oncol, Philadelphia, PA 19107 USA

[12] Ohio State Univ, Wexner Med Ctr, James Canc Ctr, Columbus, OH 43210 USA

[13] Hosp Univ Penn, Div Hematol Oncol, 3400 Spruce St, Philadelphia, PA 19104 USA

[14] Univ Virginia, Program T Cell Lymphoma Res, Charlottesville, VA USA

[15] Henry Ford Canc Inst, Detroit, MI USA

[16] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Orange, CA 92668 USA

[17] Kymera Therapeut, Watertown, MA USA

[18] Fred Hutchinson Canc Ctr, Seattle, WA USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-181130

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 3 条

[1] A Phase 1 Study of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors
Smith, Stephen D.
Starodub, Alexander
Stevens, Don A.
Shastri, Aditi
Porcu, Pierluigi
Feldman, Tatyana
Ewesuedo, Reggie
DeSavi, Chris
Dey, Joyoti
Agarwal, Sagar
Donohue, Sean
Perea, Rachelle
Klaus, Christine
Gollob, Jared
BLOOD, 2022, 140 : 12024 - 12025
[2] Phase 1 study of KT-333, a targeted protein degrader, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia, and solid tumors
Starodub, Alexander
Gollerkeri, Ashwin
De Savi, Chris
Dey, Joyoti
Agarwal, Sagar
Donohue, Sean
Perea, Rachelle
Klaus, Christine
Gollob, Jared
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[3] Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KT-253, a targeted protein degrader of MDM2, in patients with relapsed/refractory (R/R) solid tumors, lymphoma, high grade myeloid malignancies and acute lymphoblastic leukemia (ALL)
Khawaja, M. Rizwan Rizwan-Ul-Haq
Naqash, Abdul Rafeh
Schneider, Reva
Shastri, Aditi
Stahl, Maximilian
Moser, Justin C.
Karim, Nagla Fawzy Abdel
Madanat, Yazan
Jonas, Brian Andrew
Stein, Eytan
Gadgeel, Shirish M.
McCloskey, James K.
Gollerkeri, Ashwin
Perea, Rachelle
Chutake, Yogesh
Agarwal, Sagar
Henrick, Patrick
Shi, Kelvin
Daver, Naval Guastad
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 →